approach cell therapi initi w/outperform
pioneer field synthet biolog crossroad biolog
engin complex new function built live organ
compani technolog platform center use commens bacteria
genet redesign serv live therapeut two lead
product aim prevent toxic build-up wast product
patient metabol defici could deliv value-inflect clinic proof-
of-concept data within next month see true innov
biotech synthet biotic platform could glimps futur gene
therapi initi coverag outperform pt
synlog synthet biotic platform har live microb perform complex
biosynthet oper compani live microbi drug perform task
feasibl use convent enzym replac gene therapi
util entir biosynthet pathway oppos isol enzym
synthet biotic genet manipul perform commens
bacteria instead human cell
valuat center commerci potenti two clinical-stag
product product design address
seriou complic aris inherit metabol disord non-inherit
condit liver cirrhosi lead metabol dysfunct
product could demonstr clinic proof-of-concept symptomat patient
within next year
lead clinical-stag asset investig
treatment hyperammonemia toxic build-up ammonia
design biosynthet pathway effici consum ammonia
shown dose-depend preclin activ demonstr safeti healthi
volunt current test symptomat patient top-lin
data expect
design prevent toxic build-up phenylalanin
pku patient anim model drug effect scaveng phenylalanin
convert safe metabolit dose-depend fashion current
test healthi volunt expect see safeti data later year follow
potenti clinic proof-of-concept pku patient
platform technolog compani well posit attract
collabor partnership wide varieti indic believ
pipelin includ early-stag program oncolog immune-medi
disord includ on-going collabor ibd
metabol
analyst certif import disclosur see disclosur
success clinic develop
commerci launch treatment
commerci launch treatment
commerci launch treatment
non-risk-adjust sale
non-risk-adjust sale
believ synthet biotic platform
potenti address wide rang indic includ inborn
error metabol immune-medi disord cancer
valuat current center potenti lead asset
orphan indic ucd
pku well toxic ammonia build-up result liver
potenti initi phase trial ucd
potenti report interim clinic data phase
studi
potenti present initi data healthi
potenti present data sad/mad phase studi
pku patient
potenti present interim data phase trial
ucd patient
higher project peak sale model indic
earlier anticip regulatori approv commerci
launch and/or
larg non-dilut mileston payment futur
failur and/or gain approv
us eu regulatori author
delay clinic develop commerci timelin
lower anticip commerci uptak and/
price target base risk-adjust sum-of-th part npv contribut ucd
pku includ project cash per share arriv price target round
risk includ price clinic regulatori financ market competit
inc clinical-stag biotechnolog compani headquart
cambridg compani pipelin base synthet biotic
technolog platform use genet engin microb live
therapeut develop product indic includ metabol
disord inflammatori diseas cancer compani drug exploit
metabol activ microb live gut synthet biotic bacteria
reprogram metabol pathway compens
defici human host compani lead program includ
develop hyperammonemia consequ
urea cycl disord ucd liver failur lead hepat encephalopathi
second asset develop phenylketonuria pku
caus defect metabol amino acid phenylalanin
current evalu phase trial healthi
volunt cirrhosi patient elev ammonia
recent enter clinic initi phase trial healthi
volunt adult pku compani found went
public revers merger august
initi coverag outperform rate price
target next month believ compani innov
synthet biotic technolog platform potenti address mani diseas
high unmet need could offer safe effect altern
convent gene and/or enzym replac therapi view synthet
biotic could use varieti indic extend well beyond
compani current focu rare metabol diseas pipelin
earli stage program oncolog immune-medi disord includ
on-going collabor develop product inflammatori bowel
valuat current center commerci potenti two
clinical-stag product product
design address metabol complic aris inherit condit
ucd pku non-inherit condit liver cirrhosi
expect product could demonstr clinic proof-of-concept symptomat
patient within next year shown clear sign efficaci
preclin model recent present interim data first-in-human
trial healthi volunt show therapi safe
well toler compani initi phase clinic trial
liver cirrhosi patient evalu
pku patient believ clinic proof-of-concept data expect
pku could significantli de-risk therapeut pipelin
serv major catalyst share
concurr initi initi coverag
emerg biotechnolog compani alpin alpn also outperform
methodolog summar exhibit model includ contribut
two differ product three differ indic
treatment ucd probabl success regulatori approv
commerci launch treatment
po regulatori approv commerci launch
treatment pku po regulatori approv commerci
launch
believ risk adjust larg line histor data
success rate earli clinical-stag drug natur review drug discoveri
elect use lower po rel
ucd believ ucd benefit expedit pathway market
elect use discount rate program given inher
riski drug develop compani lack experi
sum-of-the-part valuat two program summar
includ project cash posit per share total npv sum
round
drug develop inher riski invest thesi depend
synlog abil success develop manufactur commerci
synthet biotic compani may experi delay complet
clinic trial result earli trial may predict result
abl success develop commerci product may
face price pressur payer could
receiv premium price orphan indic ucd pku base
preced set approv therapi ravic palynziq note
drug price orphan indic increasingli come scrutini
payer lawmak could ultim impact
major development-stag biotechnolog compani abil
maintain suffici fund critic develop progress pipelin
candid current cash flow neg model
three dilut rais may necessari sustain oper potenti
profit addit stock somewhat limit float
possibl addit suppli lock-up expire/vc holder potenti exit
pipelin clinic program
ucd
potenti initi phase trial ucd patient
potenti present interim data phase trial ucd patient
potenti report interim clinic data phase studi cirrhot
pku
potenti present initi data healthi volunt studi
potenti present data sad/mad phase studi pku patient
compani present oppenheim co estim
har therapeut power
found around highli innov modular technolog
platform develop mit util genet engin bacteria live
therapeut synlog product differ convent gene therapi three
synthet biotic engin multipl gene regulatori
element compris multi-step metabol pathway thu live microbi
drug perform rel complex metabol oper feasibl use
viral vector commonli use deliv singl transgen monogen
disord exampl convers excess ammonia safer metabolit
requir sever coordin step accomplish within singl
genet manipul perform microb onlyno human dna
alter viral vector use introduc new genet materi
synthet biotic design transit digest system
predict rate like convent drug therapeut benefit would
like depend repeat daili dose compani use natur
occur strain gut bacteria well-character probiot coli nissl
vehicl product coli nissl select specif
engraft gut microbiom dynam commun bacteria
microorgan colon digest tract strain
take long-term resid gut believ synthet biotic could provid
predict dose-depend level metabol activ synthet biotic
design safeti mind regulatori element prevent runaway activ
base feedback environment condit use turn on/off
engin compon addit synthet biotic render
auxotroph depend specif nutrit supplement surviv
fit molecular kill switch rapidli elimin product
importantli product base well-character probiot
bacteria coli nissl sold over-the-count intern
prescript us mutaflor decad coli nissl natur
occur commens gut speci non-pathogen non-colon non-
engraft non-immunogen synthet biotic differenti
live microbe-bas therapi sere therapeut ecobiot reli
engraft colon patient gut microbiom
collect believ synthet biotic offer import safeti advantag
convent gene therapi reli introduc therapeut transgen
human tissu use viral vector platform could appli
divers off-set indic span metabol diseas cancer
lead clinical-stag asset investig
treatment hyperammonemia potenti deadli condit
caus either genet defect urea cycl urea cycl disord
ucd manifest liver cirrhosi hepat encephalopathi
regardless root caus build-up ammonia blood lead overt
neurolog complic fatal ammonia major product
protein catabol healthi individu ammonia metabol urea
cycl biochem process convert ammonia urea
subsequ secret urin oper independ
ucd design scaveng ammonia convert arginin
exhibit synthet biotic design prevent toxic ammonia
effici convert ammonia arginin
strain coli nissl engin consum
ammonia upregul arginin biosynthet gene compon
natur bacteri pathway convert glutam arginin eight-step
enzymat process consum four ammonia molecul everi molecul
arginin produc comparison urea cycl consum two
molecul ammonia produc molecul urea
normal gene regul arginin biosynthesi bacteria govern
singl repressor protein argr activ presenc
arginin increas ammonia consumpt delet argr gene
replac feedback-resist biosynthet enzym
gene oper control anaerob promot select
activ gut ammonia produc schemat
modif present shown exhibit addit
hyperact arginin biosynthet pathway introduc sever
safeti featur limit reproduct capac exampl
essenti thya gene delet render strain auxotroph thymidin
mean reproduc presenc exogen
journal hepatolog volum
safeti toler establish
clinic
june initi first-in-human trial healthi
volunt trial double-blind random
placebo-control studi singl sad multipl mad ascending-dos
cohort evalu safeti toler dose gi clearanc
compani report top-lin data show safe
well toler daili dose coloni form unit cfu taken
two week higher dose led dlt includ diarrhea nausea notabl
demonstr reliabl pharmacokinet complet clear
patient within two week final dose amount
fece directli correl dose exhibit
exhibit pharmacokinet phase sad/mad studi volunt
term activ found remain metabol activ ex vivo
fece capabl convert ammonia arginin
treatment led dose-depend increas isotop label
tracer termin metabolit arginin metabol plasma
urin compar baselin suggest convert
ammonia arginin vivo exhibit appreci chang blood
ammonia level detect dose believ
expect given healthi volunt fulli function ammonia
exhibit isotop label nitrat may serv biomark
next step test symptomat patient
recent initi trial enrol patient phase
proof-of-concept trial goal show reduct serum ammonia per
cfu daili six day placebo anticip
protocol trial expect enrol patient random
top-lin result could avail addit phase studi
ucd patient slate initi top-lin result potenti
avail illustr exhibit result trial guid
design subsequ studi
exhibit clinic develop strategi
could benefit acceler regulatori path
urea cycl disord rare inborn error metabol caus
defect one protein involv urea cycl previous
mention urea cycl convert ammonia liver urea
excret urin enzym two transport protein requir
effect ammonia metabol urea cycl defect
protein contribut hyperammonemia
patient ucd ammonia concentr blood directli correl
risk neurolog symptom reduc risk patient must adher
protein-restrict diet burdensom difficult manag
elicit meaning reduct blood ammonia believ
could substanti improv qualiti life patient allow increas
protein intak reduc risk neurolog complic
ammonia valid biomark ucd believ
could benefit expedit regulatori pathway indic
ucd ultra-orphan diseas high unmet need
neurolog manifest hyperammonemia ucd patient
often short-liv includ seizur encephalopathi cerebr edema
vomit respiratori alkalosi hypothermia deadli despit
avail newborn screen identifi activ manag ucd birth
newborn ucd die sever impair earli onset
neurolog dysfunct surviv adulthood still face mortal risk
approxim mol genet metab overt
neurolog symptom often precipit stress dietari chang
apart dietari control ucd patient option control
diseas ammonia scaveng drug includ ravicti horizon pharma
approv routin use despit margin efficaci
exampl longitudin studi month ammonia scaveng reduc
percentag patient experienc hyperammonemia crisi
number crise baselin total event
total event treatment hyperammonemia crisi defin
neurolog event concurr ammonia level greater mol/l
refer upper limit normal ammonia mol/l genet
mous model ucd resolv diseas
vitro lead steadi linear reduct ammonia increas
arginin product compar ordinari coli nissl control exhibit
exhibit reduc ammonia increas arginin vitro
test vivo mous model ucd specif spfash
mous model ornithin transcarbamylas defici clear impact
blood ammonia level exhibit feed mice high-protein diet
dose-depend decreas blood ammonia accompani dose-
depend increas surviv view preclin data strongli
support evalu symptomat ucd patient current
therapeut option avail
exhibit reduc blood ammonia increas surviv mous
model ucd
market opportun ucd
preval much larger ucd estim
address patient versu address patient us
believ ucd import proof-of-concept indic would like
first commerci opportun view ucd therapi may benefit
expedit clinic strategi leverag serum ammonia surrog
estim approxim patient ucd us
eu combin assum patient activ
control diet alon approv therapi ucd benefit high
premium establish entrant ravicti
retail nearli per year achiev sale
anticip futur pushback payer drug like ravicti assum lower
price annual us eu
translat market size territori combin sale
project assum po given earli stage develop
assum approv commerci us
eu estim could gener peak risk-adjust sale
combin market
exhibit market model ucd
liver cirrhosi also lead toxic ammonia build-up
look beyond ucd market hyperammonemia also common
complic liver diseas lead cognit impair patient
mortal hepat encephalopathi common consequ cirrhosi
maintain control blood ammonia valid therapeut strategi
current investig patient previous
mention much preval ucd facilit
enrol patient clinic trial compani conduct phase
random double-blind placebo-control trial
ucd patient without cost market size sale penetr treat ucd patient without cost market size sale penetr treat profit oper expens tax probabl discount thousand npv/sharerisk adjust revenu ucd us eu outperform
approxim patient cirrhosi elev ammonia expect
top-lin result avail
rel ucd believ could difficult indic drug
develop specif patient present multipl comorbid
relationship ammonia level crisi event less clear clin
transl hepatol jun result expect
fda consid blood ammonia surrog endpoint regulatori approv
instead approv treatment typic requir demonstr reduct
event measur west criteria time hepatolog
nevertheless believ larg commerci
opportun still exist effect treatment diseas current
avail therapi mortal rate still approxim
importantli nitrogen scaveng therapi ravicti formal
approv indic demonstr abil reduc event
compar xifaxan de facto standard care hepatolog
market opportun
conserv estim market potenti
base cirrhot overtli evid diseas major liver
diseas patient occasion experi event case mild
often go untreat estim patient overt
success manag current avail option believ approxim
patient could address us eu
assum price us eu line
price xifaxan estim market size approxim us
eu combin assum po given earli stage
develop higher regulatori hurdl perceiv
indic rel ultra-orphan ucd indic model approv
commerci launch estim could gener peak
risk-adjust sale combin market
exhibit market model
aim address toxic
like synthet biotic engin
compens build-up toxic metabolit specif
design highli activ biochem pathway metabol
phenylalanin natur amino acid accumul toxic level patient
inherit genet disord pku although consequ
unmanag pku sever ucd patient pku typic
maintain strict dietari regimen avoid seriou neurolog consequ
patient pku sustain elev serum phenylalanin lead
neurocognit neuropsycholog defect includ learn disabl
attent seizur tic howev mani symptom may
readili appar patient thu maintain patient strict dietari
requir often challeng
view recent approv palynziq enzym replac therapi
develop could improv qualiti life pku
patient howev believ oral avail could provid
attract altern palynziq inject drug preclin
model shown reduc serum phenylalanin
recent initi phase trial healthi volunt
adult pku interim data healthi volunt expect
follow result pku cohort could significantli de-risk
asset
convert phenylalanin non-tox metabolit
pku caus mutat liver enzym phenylalanin hydroxylas
pah normal convert phenylalanin tyrosin liver
take advantag altern metabol pathway util enzym
us liver cirrhosi patient overtli evid patient clinicallydiagnos address treatment cost market size sale penetr treat eu liver patient overtli evid patient clinic diagnos address treatment cost market size sale penetr treat profit oper expens tax probabl discount thousand npv/sharerisk adjust revenu us eu outperform
call phenylalanin ammonia lyas pal convert phenylalanin non-tox
trans-cinnam engin overexpress pal
transport phep pump phenylalanin bacteri cytosol
process pal pal phep express
control anaerob promotor fnr
render auxotroph lysin via delet dapa gene exhibit
synlog present annual meet american societi microbiolog
preclin result support mechan action
mice non-human primat demonstr
reduc serum phenylalanin level increas level degrad
product dose-depend manner mous model pku dose
oral regular coli nissl abl reduc impact
subcutan phenylalanin challeng total serum load exhibit
exhibit blunt impact subcutan phenylalanin challeng
synlog present annual meet american societi microbiolog
vivo trans-cinnam rapidli metabol hippur ha liver
enzym excret urin virtual trans-cinnam
convert ha urin ha could serv excel biomark
activ mice excret ha urin shown directli
correl dose exhibit
exhibit urin ha output scale dose mice
synlog present annual meet american societi microbiolog
demonstr similar activ healthi non-human primat even
primat normal phenylalanin metabol capabl
discern impact serum phenylalanin excret ha level three
exhibit dose respons activ non-human primat
synlog present annual meet american societi microbiolog
collect believ preclin result point product show
dose-depend phenylalanin convers vivo support synlog
recent initi sad/mad studi healthi volunt pku patient
initi april per protocol first part
trial single-ascend dose sad studi enrol healthi volunt
evalu six dose cohort contain three drug-
treat one placebo-tr patient maximum toler dose
identifi sad cohort four pku patient enrol three drug-
next segment trial multiple-ascend dose mad
studi healthi volunt enrol four cohort contain
six drug-treat two placebo-tr patient healthi volunt
mad cohort complet singl mad cohort pku patient evalu
includ drug-treat eight placebo-tr patient expect see
earli sad/mad data healthi volunt cohort follow initi
result pku patient
benefit straightforward regulatori pathway
believ rel straightforward regulatori pathway establish
pku serum phenylalanin serv well-valid surrog endpoint
clinic trial could allow expedit pathway market
demonstr activ pku patient us eu guidelin
recommend treat pku patient target serum phenylalanin although
territori differ respect target level exhibit
exhibit target serum phenylalanin level pku therapi
note pku patient phenylalanin level mol/l restrict
protein per day patient better control phenylalanin
allow increas protein consumpt transl pediatr
reduc serum phenylalanin reflex allow higher protein
diet believ could offer patient tangibl improv qualiti
life also reduc risk seriou neurolog complic
size competit
date two drug approv fda pku biomarin
sapropterin dihydrochlorid kuvan enzym cofactor requir
function pah approv kuvan work improv pah
activ effect patient residu pah function
per mol genet metab despit lack efficaci
major pku patient kuvan net world-wide sale nearli
see biomarin palynziq formid competitor
approv may palynziq pal enzym replac strategi two
pivot open-label trial palynziq demonstr
robust abil reduc serum phenylalanin specif
patient achiev serum phenylalanin level less mol/l
mol/l mol/l respect follow-up palynziq
convinc efficaci eight-week treatment interv also
known studi depict
benchmark serum phe level vari treatment guidelinesu guidelin umol/leu pku guidelin umol/lphysiolog umol/l synlog inc
exhibit impact serum phenylalanin palynziq studi
despit efficaci believ palynziq flaw may allow
gain foothold pku market note inject palynziq caus
anaphylaxi approxim patient treatment carri black-
box warn due risk reduc risk anaphylaxi palynziq slowli
dose target mg daili cours nine week
system therapi pal enzym safe contain
within coli nissl bacteria expect trigger
anaphylaxi addit believ patient would favor oral avail
formul rel daili self-administ subcutan inject
market opportun pku
estim approxim patient live pku
us eu respect genet expect
would primarili use kuvan-refractori patient
unabl manag phenylalanin level diet restrict alon
total estim address pool approxim patient us
eu
use price estim us eu line
price palynziq estim address market size
approxim us eu territori combin sale
project assum po given earli stage develop
assum approv commerci us
eu estim could gener peak risk-adjust sale
combin market
exhibit market model
synlog discoveri stage pipelin includ sever program immuno-
oncolog ibd addit inborn error metabol ibd
program attract collabor term
agreement receiv million up-front payment decemb
payment million paid upon reach mileston abbvi
establish leader ibd space believ compani could
benefit success develop synthet biotic induc clinic
remiss case anti-tnf antibodi includ humira fail
microbiom known influenc ibd diseas state
demonstr recent random placebo-control studi fecal
microbiota transplant see lancet earli stage
investig microbe-bas therapi result bolster
confid engin synthet biotic could activ
ulcer coliti and/or crohn diseas two major form ibd
announc complet first phase on-going
collabor involv identif lead synthet biotic
product treatment ibd per term agreement receiv
mileston payment compani move second phase
collabor expect continu evalu
lead advanc preclin develop right
continu clinic develop world-wide market success
multipl discovery-stag immuno-oncolog program interplay
gut microbiom human immun system emerg
increasingli import focal area immuno-oncolog drug develop given
certain microb gut activ dendrit cell stimul pro-
pku patient patient seek cost market size sale penetr treat pku patient patient seek cost market size sale penetr treat profit oper expens tax probabl discount thousand npv/sharerisk adjust revenu phenylketonuria pku us eu synlog inc
inflammatori macrophag t-cell possibl influenc clinic respons
checkpoint inhibitor natur review microbiolog
note microbiome-focus compani includ sere evelo
enterom partnership bristol-my squibb activ immuno-
meet present earli preclin data sever
earli stage product includ syn-st syn-kyn syn-ad
develop intratumor therapi cancer syn-st
engin biosynthes sting pathway agonist ci-di-amp
promot anti-tumor immun elicit long-last local type-i interferon
respons preclin syn-st test tumor
show robust anti-tumor activ correl innate-immun
respons subsequ t-cell activ tumor associ drain
lymph node exhibit syn-kyn syn-ad design deplet
kynurenin adenosin respect tumor microenviron
intratumor syn-kyn syn-ad show synergi checkpoint inhibit
immunocompet tumor model
exhibit syn-st show anti-tumor activ preclin model
synlog present annual meet feder clinic immunolog societi
technolog platform protect extens suit patent
patent applic cover composit matter develop
manufactur formul method use genet engin bacteria
broad rang diseas indic june synlog ip portfolio
contain company-own in-licens patent patent applic
world-wide issu allow set expir
synlog lead clinic candid diseas
associ hyperammonemia ucd pku issu
allow us patent cover composit matter pharmaceut
composit lead clinic candid synlog ip portfolio includ
coverag platform treatment inborn error metabol
inflammatory/autoimmun metabol immuno-oncolog leaki gut disord
approxim million cash cash equival
market secur end april compani complet
privat placement share net addit estim
compani suffici resourc fund oper ad
multipl dilut rais model total could allow synlog
sustain oper potenti achiev sustain profit
project loss
per share respect expect see increas cash burn
associ increas sg reflect compani plan
clinic trial
believ could approv commerci ucd us
eu gener peak non-risk-adjust sale
believ could subsequ approv cirrhosis/h
gener peak non-risk-adjust sale estim
could approv commerci pku us eu
gener peak non-risk-adjust sale
introduc estim increas
introduc estim increas
assum cog therapi
believ line off-the-shelf cell therapi
interim presid chief execut offic
interim presid chief execut offic
dr aoif brennan join septemb chief medic offic
respons oversight direct compani clinic
develop strategi oper brennan previous spent six year
role increas respons recent
serv vice presid head diseas innov
includ program rang pre-clin commerci also led
program across multipl therapeut area includ late-phas
develop nusinersen spinal muscular atrophi alprolix eloct
treatment hemophilia hemophilia prior join
director clinic develop tolerx start-up biotech compani focus
immunotherapi type diabet brennan hold medic degre triniti
colleg dublin ireland complet post-gradu train intern
medicin endocrinolog metabol complet post-doctor
train clinic research metabol beth israel deaco medic
center boston graduat harvard medic school scholar
todd shegog join septemb chief financi offic
respons oversight direct compani financi strategi
manag well facil inform system shegog bring
year financi experi biotechnolog
pharmaceut industri recent serv senior vice presid
chief financi offic respons
financ oper inform system support pursuit
innov therapi schizophrenia alzheim diseas prior forum
shegog senior vice presid chief financi offic millennium
pharmaceut inc takeda oncolog respons
manag compani financi resourc corpor plan financi
report complianc tenur shegog held key
leadership role support earli evolut compani
transform genom compani fulli integr drug develop
approv launch flagship oncolog product velcad
billion acquisit millennium began career
healthcar genet institut varieti financi posit
support research develop organ member
commerci oper team support launch benefix shegog
hold mba tepper school manag carnegi mellon
univers bachelor degre electr engin lafayett
dr paul miller join chief scientif offic
account aspect discoveri research platform expans
compani previous miller vice presid infect biolog
astrazeneca respons earli discoveri portfolio
strategi also lead sever extern collabor prior astra-zeneca
chief scientif offic antibacteri research lead
discoveri team produc eight drug develop candid provid
critic research support sever success market antibiot includ
zithromax zyvox also success advanc novel oxazolidinon
sutezolid tuberculosi phase ii studi microbi geneticist
train miller began profession career warner-lambert compani
ann arbor mi integr modern molecular-genet approach
tradit antibacteri drug discoveri program establish novel target
discoveri project work led new insight mechan
bacteria sens respond antibiot environment agent
miller receiv phd microbiolog immunolog albani medic
colleg conduct post-doctor studi nation institut
also serv member institut medicin forum
sec file oppenheim co research
figur thousand except per share expens good sold research develop gener administr oper loss incom expens interest invest interest incom expens loss incom incom incom loss unreal loss market incom per share share outstand comark breidenbach outperform
sec file oppenheim co research
figur thousand except per share asset cash prepaid expens current current properti equip long term invest restrict liabil account accru expens current dever current leas incent oblig net current defer defer revenu net current portion relat long-term liabilitiestot contingenciespref stockstockhold equitycommon addit paid-in accumul comprehens accumul stockhold liabil stockhold synlog inc
stock price compani mention report close
